Clinical trial
Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or…
NCT00052390 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00052390 |
|---|---|
| Title | Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma |
| Official title | A Multi-Institutional, Open-Label, Phase II Study Of Doxorubicin And Bevacizumab (Anti-VEFG Monoclonal Antibody, NSC 704865) For Patients With Advanced Or Metastatic Soft-Tissue Sarcoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, doxorubicin hydrochloride |
| Start date | Oct 1, 2002 |
| Completion | Oct 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: